» Articles » PMID: 35740561

A Platform of Patient-Derived Microtumors Identifies Individual Treatment Responses and Therapeutic Vulnerabilities in Ovarian Cancer

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Jun 24
PMID 35740561
Authors
Affiliations
Soon will be listed here.
Abstract

In light of the frequent development of therapeutic resistance in cancer treatment, there is a strong need for personalized model systems representing patient tumor heterogeneity, while enabling parallel drug testing and identification of appropriate treatment responses in individual patients. Using ovarian cancer as a prime example of a heterogeneous tumor disease, we developed a 3D preclinical tumor model comprised of patient-derived microtumors (PDM) and autologous tumor-infiltrating lymphocytes (TILs) to identify individual treatment vulnerabilities and validate chemo-, immuno- and targeted therapy efficacies. Enzymatic digestion of primary ovarian cancer tissue and cultivation in defined serum-free media allowed rapid and efficient recovery of PDM, while preserving histopathological features of corresponding patient tumor tissue. Reverse-phase protein array (RPPA)-analyses of >110 total and phospho-proteins enabled the identification of patient-specific sensitivities to standard, platinum-based therapy and thereby the prediction of potential treatment-responders. Co-cultures of PDM and autologous TILs for individual efficacy testing of immune checkpoint inhibitor treatment demonstrated patient-specific enhancement of cytotoxic TIL activity by this therapeutic approach. Combining protein pathway analysis and drug efficacy testing of PDM enables drug mode-of-action analyses and therapeutic sensitivity prediction within a clinically relevant time frame after surgery. Follow-up studies in larger cohorts are currently under way to further evaluate the applicability of this platform to support clinical decision making.

Citing Articles

Functionally-instructed modifiers of response to ATR inhibition in experimental glioma.

Walter B, Hirsch S, Kuhlburger L, Stahl A, Schnabel L, Wisser S J Exp Clin Cancer Res. 2024; 43(1):77.

PMID: 38475864 PMC: 10935927. DOI: 10.1186/s13046-024-02995-z.


Patient-Derived Organoids as Therapy Screening Platforms in Cancer Patients.

Khorsandi D, Yang J, Foster S, Khosravi S, Kouchehbaghi N, Zarei F Adv Healthc Mater. 2024; 13(21):e2302331.

PMID: 38359321 PMC: 11324859. DOI: 10.1002/adhm.202302331.


Emerging roles of 3D-culture systems in tackling tumor drug resistance.

Nikdouz A, Orso F Cancer Drug Resist. 2024; 6(4):788-804.

PMID: 38263982 PMC: 10804388. DOI: 10.20517/cdr.2023.93.


Can Nitric Oxide-Based Therapy Be Improved for the Treatment of Cancers? A Perspective.

Sinha B Int J Mol Sci. 2023; 24(17).

PMID: 37686417 PMC: 10487592. DOI: 10.3390/ijms241713611.


Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment.

Anderle N, Schafer-Ruoff F, Staebler A, Kersten N, Koch A, Onder C J Exp Clin Cancer Res. 2023; 42(1):210.

PMID: 37596623 PMC: 10436441. DOI: 10.1186/s13046-023-02782-2.

References
1.
Farley J, Brady W, Vathipadiekal V, Lankes H, Coleman R, Morgan M . Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2012; 14(2):134-40. PMC: 3627419. DOI: 10.1016/S1470-2045(12)70572-7. View

2.
Zhang H, Liu T, Zhang Z, Payne S, Zhang B, McDermott J . Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. Cell. 2016; 166(3):755-765. PMC: 4967013. DOI: 10.1016/j.cell.2016.05.069. View

3.
Leontieva O, Blagosklonny M . DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging (Albany NY). 2011; 2(12):924-35. PMC: 3034181. DOI: 10.18632/aging.100265. View

4.
Aramburu J, Ortells M, Tejedor S, Buxade M, Lopez-Rodriguez C . Transcriptional regulation of the stress response by mTOR. Sci Signal. 2014; 7(332):re2. DOI: 10.1126/scisignal.2005326. View

5.
Liu S, Sun J, Cai B, Xi X, Yang L, Zhang Z . NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer. Tumour Biol. 2016; 37(7):9671-80. DOI: 10.1007/s13277-016-4848-x. View